Anti-Cisplatin modified DNA抗体[CP9/19] (ab103261)
Key features and details
- Rat monoclonal [CP9/19] to Cisplatin modified DNA
- Suitable for: ELISA
- Reacts with: Species independent
- Isotype: IgG2a
概述
-
产品名称
Anti-Cisplatin modified DNA抗体[CP9/19] -
描述
大鼠单克隆抗体[CP9/19] to Cisplatin modified DNA -
宿主
Rat -
经测试应用
适用于: ELISAmore details -
种属反应性
与反应: Species independent -
免疫原
Full length protein corresponding to Cisplatin modified DNA. Cisplatin Modified Native DNA.
-
阳性对照
- RNA/DNA.
-
常规说明
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
存储溶液
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
纯度
Protein A/G purified -
Primary antibody说明
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. -
克隆
单克隆 -
克隆编号
CP9/19 -
骨髓瘤
Y3/Ag1.2.3 -
同种型
IgG2a -
研究领域
相关产品
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab103261于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
ELISA | (1) |
Use at an assay dependent concentration.
|
说明 |
---|
ELISA
Use at an assay dependent concentration. |
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
SDS download
-
Datasheet download
文献 (41)
ab103261 被引用在 41 文献中.
- Winardi D et al. Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model. Int J Mol Sci 23:N/A (2022). PubMed: 35163790
- Tangeda V et al. Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells. Cell Death Dis 13:241 (2022). PubMed: 35296653
- Jones TM et al. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. Cell Death Dis 13:350 (2022). PubMed: 35428778
- Nicholson HA et al. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. Br J Cancer 127:1340-1351 (2022). PubMed: 35778553
- Zhang Y et al. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis 12:12 (2021). PubMed: 33414468